Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I read that blog and it was just a blog with everything the company has accomplished in a short period of time up until now with links...and as all of their articles...that they all write on there...it is just their opinion...albeit with a slew of facts and links to back up all the progress that the company has made so far...good job...
bull
He was talking about the steps we have to get to the IND taking a few months...that's all
bull
and you have to know how to spot the right company and...PMCB...it was easy for me with this one...I bought after Ken Waggoner came on board...by today's PR it looks like I made the right decision...
bull
PharmaCyte Biotech Begins Phase 2b Clinical Trial Push With Imaging Endpoints Contract for Radiological Imaging
PharmaCyte Biotech, Inc.
September 9, 2015 9:30 AM
GlobeNewswire
????
SILVER SPRING, Md., Sept. 09, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has contracted with Imaging Endpoints in Scottsdale, Arizona, to perform radiologic imaging that will be required for PharmaCyte Biotech’s Phase 2b clinical trial in pancreatic cancer. This is the first in a series of announcements that PharmaCyte will release related to the company’s upcoming Phase 2b clinical trial, including a full layout of the dramatically improved clinical trial design. The trial will test the effectiveness of PharmaCyte Biotech’s pancreatic cancer treatment (the combination of microcapsules produced using the Cell-in-a-Box® technology and low doses of the anticancer drug ifosfamide) in patients with this disease.
The involvement of Imaging Endpoints in the Phase 2b trial will be extensive and marks the first of many crucial events related to the start of PharmaCyte’s first clinical trial. Experts from Imaging Endpoints will be involved in training radiologists at the various study sites to ensure the Cell-in-a-Box® capsules are correctly implanted into patients. Imaging Endpoints will also be responsible for coordinating the data obtained from CT (computerized tomography) and PET (positron emission tomography) scans of the patients’ tumors as they progress through the clinical trial. Imaging Endpoints will also analyze all of the imaging data obtained during the trial using state-of-the-art methodology.
In addition to outstanding radiologists, Imaging Endpoints' Scientific Advisory Board members include world renowned experts in pancreatic cancer. Dr. Daniel D. Von Hoff, Chief Development Officer of Translational Drug Development (TD2), the Contract Research Organization currently performing preclinical studies in the U.S. for PharmaCyte Biotech, is Chairman of the Scientific Advisory Board and Dr. Manuel Hidalgo, a member of that same Board, is also a member of PharmaCyte Biotech’s Scientific Advisory Board and a consultant to PharmaCyte Biotech. Imaging Endpoints currently has 40 “in-house’ radiologists who are working on about 100 clinical trials in various therapeutic areas.
PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented, “We are extremely pleased that Imaging Endpoints has agreed to perform some of the most critical activities related to our upcoming trial in pancreatic cancer. The success of this trial will be, in large part, crucial to the overall success of our company. The outstanding individuals associated with Imaging Endpoints and the expertise of that company in analyzing the radiologic imaging results from the trial will, we believe, ensure that the interpretation of those results is both comprehensive and accurate. With Imaging Endpoints, we could not be in better hands.”
“We are honored to be working with PharmaCyte Biotech on this exciting project,” stated Imaging Endpoints’ Founder and Chief Medical Officer, Ron Korn, M.D., Ph.D. “PharmaCyte Biotech has assembled an impressive team of experts to conduct this study and, if successful, their technology promises to provide a new approach for the treatment of pancreatic cancer.”
Once the market figures out the technolgy in the video IS GROUNDBREAKING it will be worth all of the crap we have had to endure...
bull
WOW...All that in under 4 minutes on Discovery Channel...
enough said....
Little Hidden Gem of a bio all grown up...
bull
"Over 700 million people have viewed the NewsWatch series, making it one of the most successful independently produced news magazines on television. NewsWatch will present PharmaCyte Biotech’s story in “HealthWatch,” a segment that provides viewers with the latest medical breakthroughs and newest medical advances that can improve their health."
bull
PharmaCyte Biotech is Going On the Air (AMGN, PMCB, CELG)
Look out Celgene Corporation (NASDAQ:CELG), Amgen, Inc. (NASDAQ:AMGN), and any other high-profile biotech company out there. A small company with a great biotechnology may be about to steal some of your publicity thunder. PharmaCyte Biotech Inc. (OTCMKTS:PMCB) is getting some national television airtime on Tuesday, which could put PMCB "on the map" even more so than it is now.
For those not familiar with it, PharmaCyte Biotech is the name behind the so-called "Cell in a Box" technology that allows for the (successful) encapsulation of live cells that can be deposited into the human body. Though PMCB has this far kept its focus on using this technology as a means of fighting pancreatic cancer as well as type 1 diabetes - though brain cancer is also on the horizon - the possibilities of a long-lasting capsule are extensive. The biotechnology achieves one of the medicine world's proverbial holy grails... the insertion of living cells into a patient without the risk of that patient's own immune system ultimately destroying those outside cells.
A whole lot more people are in a position to be impressed by the Cell-in-a-Box technology as of Tuesday morning (June 30th) though. That's when PharmaCyte Biotech and its novel approach toward treating diabetes and cancer will be highlighted on national television.
The program is called NewsWatch - an independently-produced news magazine aired on the Discovery Channel and the ION Network. The program featuring PharmaCyte will air between 7:00 am and 7:30 am EDT and also the same times in the PDT time zone.
This is more than just a step forward for PharmaCyte's publicity effort. The program is available in more than 96 million households... nearly all cable-subscribers. Even if only a handful of them see the segment featuring Cell-in-a-Box, it's going to be a whole lot of new parties interested in what the company's doing. That's good for current PMCB shareholders, as that interest could lead to buying, putting bullish pressure on the stock. It wouldn't be the first time this kind of widespread TV attention has been good for a stock's price.
In any case, anyone reading this is clearly an interested party. Be sure to tune in Tuesday morning, or set your DVR to record the program. You might just pick up a new data nugget or two about PharmaCyte.
http://www.smallcapnetwork.com/PharmaCyte-Biotech-is-Going-On-the-Air-AMGN-PMCB-CELG/s/via/10/article/view/p/mid/3/id/550/
I think I would go with the experts....and we have quite an impressive list building up...PMCB is turning out to be the great hidden gem just like I thought...
I CAN NOT WAIT FOR TD2 RESULTS...
bull
Yes, Cell in a Box can encapsulate stem cells but PMCB only owns the rights to melligen cells and cells capable of activating ifosfamide... the company does not own the rights to use stem cells.
bull
PHARMACYTE BIOTECH DOES NOT PROMOTE STEM CELL....WE HAVE NOTHING TO DO WITH THEM.....
bull
Cell-in-a-Box(R) Technology3 Small-Cap Biotech Stocks That Are Challenging the Status Quo
WHITEFISH, MT / ACCESSWIRE / June 29, 2015 / Small-cap biotech stocks have been top performers so far this year, with the PowerShares S&P SmallCap Healthcare ETF (PSCH) returning 25%, which is 5x better than the SPDR S&P 500 ETF's (NYSE:SPY) 5% return. Investors may want to consider adding exposure to this asset class given its outperformance and lower correlation with the overall U.S. equity market.
In this article, we'll take a look at three micro-cap and small-cap companies that are taking a different approach to the status quo within multi-billion dollar industries.
eBalance Technology
Diabetes, a disorder of blood sugar metabolism, is a prevalent and serious disease of major public health importance. Currently there are approximately 387 million people in the world living with diabetes with an expected increase to nearly 600 million by 2035. Diabetes has major adverse effects on people's health, but also presents a large economic burden. Global healthcare expenditures on diabetes currently exceeds $420B. Experts agree that a significant portion of the morbidity, mortality and cost of diabetes could be avoided with improved control of blood sugars.
Cell MedX Corp. (CMXC) has discovered a potentially valuable new, proprietary technology for the treatment of diabetes - one that encompasses electrical micro-currents delivered in distinctive patterns of waveform, amplitude, frequency, and duration leading to alterations in metabolic pathways which may result in improved blood sugar control. The treatment is believed to be of exceptionally low risk, and can be self administered at home. It is a uniquely new category of treatment.
In a pilot clinical discovery phase trial in two diabetic subjects, the company found that its e-Balance technology increased sensitivity to insulin and up-regulated glycolytic processes, with subjects demonstrating enhanced glucose utilization.
Further explorations of these pathways will continue, along with endpoints like HbA1C, in an expanded clinical trial that is currently recruiting subjects in Newport Beach, CA.
Investors in Cell MedX can look forward to multiple potential catalysts in the near future including a series of clinical trials, expanded basic research, intellectual property pursuits, exploration of new form factors with innovative industrial designs, and growth and expansion of the enterprise as their technology is productized and readied for introduction into a global market.
BACcel Platform
Drug resistant organisms and hospital-acquired infections have become an enormous global problem, especially given the lack of new antibiotics capable of fighting these serious infections. According to the CDC, one in five hospital patients has at lest one healthcare-associated infection. Accelerated Diagnostics Inc. (NASDAQ:AXDX) aims to rapidly identify these pathogens for treatment.
While traditional testing to determine a pathogen's susceptibility to a certain antibiotic may take upwards of 50 hours, which is often too late to help patients, the company's BACcel platform is capable of performing the analysis in just three steps taking less than five hours to complete. These tests have 98% sensitivity (identification of target) and 97% specificity (identification of non-target).
The company plans on launching its Accelerate ID/AST System in the U.S. in early 2016, after having initiated its BSI trial and secured a CE Mark in mid-2015. Over the long-term, the company could capture a significant piece of the $7.5 billion (estimated 2019) market with peak gross margins of over 70% - an attractive proposition for investors in the biotechnology space.
Cell-in-a-Box(R) Technology
Pancreatic cancer is one of the deadliest forms of cancer, with less than half of patients surviving more than a year. In addition to the diseases rapid progression, many patients experience unbearable and, unfortunately, untreatable pain from malignant fluid (known as ascites) in the abdominal cavity. PharmaCyte Biotech Inc. (PMCB) is attempting to combat both the cancer and its side effects.
Rather than injecting patients with high doses of toxic chemotherapy drugs, the company's approach is to place its Cell-in-a-Box(R) ifosamide-activating capsules in close proximity to the tumor and then intravenously inject low doses of ifosamide - a cancer-killing drug - to attack the tumor. Unlike other approaches, there's no immune response or damage to tissue near where the capsules are placed.
The company has demonstrated the effectiveness of the low dosage (as opposed to regular dosages that harms the body) in two early clinical trials and is preparing to conduct a more advanced Phase 2b clinical trial in the near future. Early evidence also suggests that the treatment may be effective in delaying the accumulation of ascites fluid in mice bearing an aggressive form of ovarian cancer.
Key Takeaway Points
Small-cap biotech stocks have been top performers so far this year and they don't seem to be ready to stop anytime soon. Investors looking for exposure to the industry may want to consider small-cap opportunities in the space, such as the three companies discussed in this article, which are targeting multi-billion dollar industries with platform technologies.
"Our mission is about helping people. We can think of no better way to connect with people than to have our compelling story air on the Discovery Channel and ION Network and potentially be seen by the 96 million households they reach in the U.S.”
I wouldn't worry about that...
bull
"PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented, “We have a great story, and when we were contacted by NewsWatch to present our technology and the targeted treatments we’re developing for cancer and diabetes to their nationwide audience, we jumped at the opportunity. Our mission is about helping people. We can think of no better way to connect with people than to have our compelling story air on the Discovery Channel and ION Network and potentially be seen by the 96 million households they reach in the U.S.”
bull
"NewsWatch will present PharmaCyte Biotech’s story in “HealthWatch,” a segment that provides viewers with the latest medical breakthroughs and newest medical advances that can improve their health."
bull
PharmaCyte Biotech’s Cancer and Diabetes Treatments Airing Nationwide on Discovery Channel
SILVER SPRING, Md., June 29, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its technology and treatments will be featured on the Discovery Channel and ION Network tomorrow morning, June 30, 2015, from 7:00-7:30 a.m. EDT and PDT, except on DISH Network which airs using the EDT time zone. PharmaCyte Biotech’s story will air on Discovery Channel and ION Network’s news magazine series “NewsWatch,” a source for breaking consumer, technology, travel, health and entertainment news since 1990.
NewsWatch, based in the Washington, DC area, airs nationwide in the U.S. and can be seen in virtually every market throughout the country. Each edition of NewsWatch reaches more than 96 million U.S. households. Over 700 million people have viewed the NewsWatch series, making it one of the most successful independently produced news magazines on television. NewsWatch will present PharmaCyte Biotech’s story in “HealthWatch,” a segment that provides viewers with the latest medical breakthroughs and newest medical advances that can improve their health.
PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented, “We have a great story, and when we were contacted by NewsWatch to present our technology and the targeted treatments we’re developing for cancer and diabetes to their nationwide audience, we jumped at the opportunity. Our mission is about helping people. We can think of no better way to connect with people than to have our compelling story air on the Discovery Channel and ION Network and potentially be seen by the 96 million households they reach in the U.S.”
Since the series began in 1990, NewsWatch has featured more than 10,000 individual stories on a wide range of subjects, including medical breakthroughs, finance, travel, new product introductions, public policy issues, entertainment, celebrities and numerous other topics.
Do you have any idea of the amount of people that are up at that time...
oh, there will be no problem with people seeing PharmaCyte Biotech on a show that is exactly suited for it...
and all those ( As seen on TV ) ads coming our way ...
bull
ABOUT TIME PharmaCyte Biotech and especially Cell-in-a-Box got the recognition we all know it deserves...I am right there with you BioNewton....
bull
I would appreciate some proof of this rumor that is being passed around..."cell it the box doesn't work"...until then I choose to just wait for the REAL RESULTS...
and it is called Cell-in-a-Box...
bull
I think it is a great pps anywhere in here...one day this pps will be a huge joke...I also bought more...
bull
Did you see how little it took to sell the stock down this morning....don't be fooled into thinking there is a lot of selling going on...this has been a buying opportunity for my group...
bull
Sounds like too much speculation for me...I think I am fine just waiting for the real results...
bull
Who in their right mind would short this stock right here...with results coming...
bull
thanks Pete...same to you...how did you like the company's awesome video...
https://www.youtube.com/embed/VBebR1vWt50
everything we believe about this little bio...
bull
The company's CEO and COO were not the only ones at ASCO...I heard there was also a bright light...CIAB made an appearance...
and this awesome video seemed to make a big splash there ...
https://www.youtube.com/embed/VBebR1vWt50
this summer is going to get interesting....
bull
Results from trials can take a bio from being a penny stock to not in a matter of days...a partner or buyout can change everything so as moving to another exchange doesn't matter...
bull
If I were you I would be totally focused on Dr. Von Hoff's TD2 ascites and pain for ALL CANCERS study which is imminent...any time results could be shown now...that is the key right now...
bull
Could be Wendy...he was hired for a very specific purpose and with the work he did at Pfizer it is not just his scientific background...it is his knowledge of science to use for the financial M & A...
with that and the fact that Von Hoff's results are imminent any time now...I would not be relinquishing any of my shares...
bull
There is nothing on the chart at .20 for resistance...it is just a psychological even number...wants to break out bad...but a close over the 200dma is good...
bull
I don't know about that...Fridays have been holding...I think more and more people are wondering when the morning will come with Von Hoff's results...so maybe they are holding too...
bull
not hearing something about PharmaCyte outside of these message boards should not be surprising...the majority of people don't do their own investing or invest at all...and if they do it is in a 401...these people are just learning what all of us LONGS have known all along...and Liquard is just a piece of the puzzle...
bull
Another GOOD trading day here...stayed above the 100dma and closed above the fib level...
bull
0.0043 down...that is not dumping...lol
bull
PharmaCyte Biotech Appoints Former Pfizer and Alchemia Executive to Board of Directors
Nasdaq
By GlobeNewswire, April 14, 2015, 09:30:00 AM EDT
SILVER SPRING, Md., April 14, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Thomas Liquard has joined its Board of Directors and will become Chairman of the Audit Committee. Mr. Liquard is a seasoned pharmaceutical industry executive whose past experiences include serving as Chief Executive of Alchemia Limited and as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio for Pfizer in New York.
"On behalf of our management team and Board of Directors, it is a pleasure to welcome Thomas to PharmaCyte Biotech. His specific healthcare sector expertise across product and business development, commercialization and managerial leadership will be an invaluable asset to our team as the PharmaCyte Biotech enters its next phase of growth," commented Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech.
Mr. Liquard stated, "I firmly believe that PharmaCyte Biotech's future is bright, both in the areas of oncology and diabetes. Its use of the platform live-cell encapsulation technology, known as Cell-in-a-Box®, gives PharmaCyte Biotech opportunities to develop unique treatments for serious and deadly forms of cancer as well as for insulin-dependent diabetes. This is an exciting time for PharmaCyte Biotech and I am thrilled to join the company, as it pursues programs that have the potential to change how patients with these diseases are treated."
Mr. Liquard has more than a decade of experience in the pharmaceutical industry, having held various commercialization, product development and leadership roles with big pharma and biotech companies. Most recently, Mr. Liquard was CEO of Alchemia Limited, a major Australian biotech company (ASX:ACL) with an FDA approved sterile injectable and a late stage oncology platform.
Prior to joining Alchemia, Mr. Liquard spent seven years with Pfizer in New York where he held various commercial roles of increasing scope and responsibility, including most recently as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio. Mr. Liquard also spent three years as a key member of the company's EP US Brands P&L Leadership Team. In this role, he engineered the group's 505(b)(2) investment strategy, culminating in the $700M acquisition of NextWave Pharmaceuticals. He also led the NextWave pre- and post- acquisition integration efforts. In addition, Mr. Liquard worked as a Director within the New Product Planning and Portfolio & Decision Analysis groups at Pfizer. There he was responsible for formulating investment decisions on business development opportunities and internal development programs across multiple therapeutic areas, including oncology, central nervous system and metabolic diseases.
Mr. Liquard holds an MBA from Columbia Business School and a Bachelor of Science degree from the University of Southern California.
http://www.nasdaq.com/press-release/pharmacyte-biotech-appoints-former-pfizer-and-alchemia-executive-to-board-of-directors-20150414-00683
WE HAVE FDA ORPHAN DRUG DESIGNATION ALREADY...THE GOLDEN ODD OF APPROVALS...I do not get DWELLING on this subject...
bull
Yes we know that...and that time is coming...why do you think we are all loading up shares at these ridiculous prices...and don't think that this company has to have an approval for this stock to fly...
bull
the bigger stock...what is that???....
and I didn't buy at .50 ...I owned this stock before it even made the bigger move up...so I wouldn't go making accusations about things you don't know...
have a great day
bull
There is a BIG SHOCK coming your way if you think the cancer thing (as you put it) is not working...
have a nice day mixer
bull
There are some that want to ignore the FACT that Dr. Von Hoff is the chief architect and developer of our preclinical studies at TD2...no matter...we should be hearing results in the near future on CIAB for ALL CANCERS
bull
What is going to move PharmaCyte stock is the science of Cell-in-a-Box for ALL CANCERS AND DIABETES...which is starting to manifest and show itself...no need to worry about the shorting or the traders...stock will take care of itself and them in the near future...
bull